Cleveland Clinic Otolaryngology - Head & Neck Surgery的动态

???Next Presentation at the OTS Congress in Montreal-Canada??? ? We are delighted to announce that we will be presenting a poster (#P076) at the Oligonucleotide Therapeutics Society (OTS) Congress on Monday, October 7, from 5:00 p.m. to 8:00 p.m. ? Our poster is titled "Innovations in Oligonucleotide Therapeutics Manufacturing to Responsibly Meet Future Demand" and addresses the growing interest in oligonucleotide-based therapeutics, especially in the development of molecules for non-rare diseases. With more than 700 molecules in development, it is crucial to consider the manufacturing challenges that arise with this increase in production. ? At Sylentis, we are committed to sustainability in oligonucleotide manufacturing. We are exploring new methodologies that not only improve purity and quality, but also reduce waste and resource consumption. Our approach includes the use of natural resins in chromatography, which allows up to 80% of the water used in the process to be recovered. ? We look forward to seeing many of you at the conference and sharing ideas on how we can move towards a more sustainable future in therapeutics manufacturing. ? See you soon! ? #OTS2024 #Oligonucleotides #Sustainability #Innovation

Product Citation: In a study published by APRINOIA Therapeutics, StressMarq's fibrillar and oligomeric #AlphaSynuclein & #AmyloidBeta constructs contributed to the development of a novel ELISA for the detection of oligomeric #Tau. αSyn: https://bit.ly/48w0J27 ?? Amyloid β: https://bit.ly/499p5iK ?? Tau: https://bit.ly/3RKlyli ? Full paper: https://bit.ly/414IBfY

?? Next Presentation at the OTS Congress in Montreal-Canada ?? We are excited to announce that we will be presenting a poster (#P076) at the Oligonucleotide Therapeutics Society (OTS) Congress on Monday, October 7, from 5:00 p.m. to 8:00 p.m. Our poster is titled "Innovations in Oligonucleotide Therapeutics Manufacturing to Responsibly Meet Future Demand" and addresses the growing interest in oligonucleotide-based therapeutics, especially in the development of molecules for non-rare diseases. With more than 700 molecules in development, it is crucial to consider the manufacturing challenges that arise with this increase in production. At Sylentis, we are committed to sustainability in oligonucleotide manufacturing. We are exploring new methodologies that not only improve purity and quality, but also reduce waste and resource consumption. Our approach includes the use of natural resins in chromatography, which allows up to 80% of the water used in the process to be recovered. We look forward to seeing many of you at the conference and sharing ideas on how we can move towards a more sustainable future in therapeutics manufacturing. See you soon! #OTS2024 #Oligonucleotides #Sustainability #Innovation

Producing engineered extracellular vesicles for therapeutics applications: in this study, Kristin Luther, Joe Nabhan at Vesigen Therapeutics, Inc. and collaborators evaluated two scalable strategies for generating GFP-loaded ARMM-engineered EVs: transient transfection and stable cell line-based production. The upstream ARMM production processes used a suspension HEK293-derived line called 5B8 from Lonza, with production assessed in both shake flasks and bioreactors. For downstream ARMM purification, they employed Tangential Flow Filtration and Anion Exchange Chromatography https://lnkd.in/eWs8TfSM In vivo, ARMMs demonstrated rapid biodistribution, primarily to the spleen and liver, with lesser distribution to the kidneys and lungs. The successful scale-up of ARMM production highlights the potential of engineered EVs. An article also authored by Ali Navaei, Leah Gens, Carson Semple, Pearl Moharil, Ilaria Passalacqua, Komal Vyas, Qiyu Wang, Shu-Lin Liu, Lucy Sun, Senthil Ramaswamy and Davide Zocco #extracellularvesicles #exosomes #bioengineering #translationalmedicine #cellculture #Vesiculab

This week at?#TIDESUSA,?John Lewis, CEO of Entos Pharmaceuticals will present on our Fusogenix Proteo-Lipid Vehicle Drug Delivery Platform, on Thursday, May 16 at 2:30 pm ET. Want to connect? DM?John Lewis?or CSO?Arun Raturi to meet to talk about the next generation of non-viral delivery! #TIDESUSA?#OligonucleotidePeptideTherapeutics?#EntosSpeaks?#Fusogenix?#PLVs?#nucleicaciddelivery?#geneticmedicines #biotechnology

Update on SA’s astaxanthin developments: ·????????Founded and spun off Adjuvia Therapeutics, Inc. (ATI) ·????????ATI working towards qualifying our nano emulsified astaxanthin through an Investigational New Drug Application (IND) ·????????Our works are building a strong case for our nano emulsified astaxanthin molecule has the highest bioavailability and efficacy with respect to mitochondrial function. ·????????This is building on validations long in place at SA. ·????????SA has proven that our nano emulsified 3S, 3’S astaxanthin molecular complex: o??Increases yolk volume in broodstock o??Increases immunity in ornamental fish o??Increases color, growth rate, yield and immunity and color in salmon at greater cost efficiency than synthetic astaxanthin o??Increases growth rate in larvae, rotifers and amphibians. o??Is one of the enabling factors in new SOPs for successful production of pelagic spawners.?

The world of oligonucleotide therapeutics can feel like you’re in uncharted territory. Cytiva can be your guide. Learn what you need to know in our brand-new oligo infographic – everything from future-proofing to synthesis, purification, and filtration. https://lnkd.in/dES3fw2F #oligos #nucleicacids #oligonucleotides #genomicmedicine

Consistency of product quality is important in biopharma.?Oligonucleotides have grown to represent an increasingly important class of therapeutic modalities. During the development of new chemical entities, it is critical to both determine sequences and identify process impurities and degradation pathways using LC/MS. In this webinar, gain background knowledge on oligonucleotide therapeutics, focusing mostly on siRNA and understand the importance of structure characterisation and impurity identification: https://buff.ly/4do4CbT #ChemetrixAcademy #Webinar #Biopharma #Chromatography #Spectrometry

?? New product announcement: SmartSphero Plates (SSP) — Easiest and standardized way to start, organoids or spheroids culture. ?? Results of a long-term collaboration between 2 companies, the SSP has been designed by 4Dcell and exclusively distributed by Cherry Biotech. The SmartSphero Plates (SSP) is an ideal starter kit for researchers in laboratories and pharmaceutical companies looking to start or explore organoids and spheroids culture. Key benefits: ? Reproducible with < 10% in organoid size variability ? No organoid loss during medium replacement ? Compatible with all adherent cells (immortalized, primary, dissociated) ? Enhanced detection of soluble factors thanks to the high number of organoids per well ??Cherry on the cake, SSP organoids can be vascularized for more complex 3D models when combined with our CubiX - Microphysiological platform. For more details and to place your order, visit our page: https://lnkd.in/eJS3XrB7 #3dcellculture #organoids #vascularized #immunocompetent #organonchip #alternativestoanimaltesting

?? Who could have thought that merging micropatterning, standardization and engineering can have a huge impact on the way organoids and spheroids are cultured, and imaged? ?? Easy imaging, no spheroid or organoid loss during medium renewal, high degree of size homogeneity, and no organoid merging looks like a dream, right? ?? ?? The SmartSphero Plate by 4Dcell allows make this dream come true, and cherry on the cake, it is now exclusively distributed by Cherry,